3,4,5-trisubstituted-1,2,4-triazoles and 3,4,5-trisubstituted-3-thio-1,2,4-triazoles and uses thereof
The present disclosure describes novel compounds that are somatostatin receptor type 4 agonists. The present disclosure is also directed to a compound of Formula (II):
1. A compound of Formula (II):
wherein
are independently a single bond or is absent;
A is C(H) or N;
B and C are independent C(H), N, N(H), O, or S, provided that when B or C is C(H) or N, is a single bond, and when B or C is N(H), O, or S, is absent;
D is S, O, NR 16 , P, sulfone, or sulfoxide, wherein R 16 is hydrogen, C 1 -C 6 alkyl, aryl, or benzyl;
R 1 and R 7 are independently hydrogen, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted C 1 -C 6 alkyl, substituted or unsubstituted cycloalkyl or substituted or unsubstituted fused ring system;
R 2 is substituted or unsubstituted C 1 -C 6 alkyl;
R 3 , R 4 , and R 5 are independently hydrogen, F, Cl, Br, I, substituted or unsubstituted alkyl, substituted or unsubstituted alkoxy, substituted or unsubstituted amine, thiosulfinate, thiosulfonate, thioamide, sulfimide, sulfoximide, sulfonediimine, or sulfur halide;
R 6 and R 8 are independently hydrogen, F, Cl, Br, I, substituted or unsubstituted C 1 -C 6 alkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, or substituted or unsubstituted cycloalkyl; and
R 9 and R 15 are independently substituted or unsubstituted C 1 -C 6 alkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, or substituted or unsubstituted cycloalkyl;
or a pharmaceutically acceptable salt thereof.
2. The compound of claim 1 , wherein are each a single bond and A, B, and C are N.
3. The compound of claim 1 , wherein D is S, sulfone, or sulfoxide.
4. The compound of claim 1 , wherein R 9 is substituted or unsubstituted C 1 -C 3 alkyl.
5. The compound of claim 1 , wherein R 15 is unsubstituted C 1 -C 3 alkyl.
6. The compound of claim 1 , wherein R 6 and R 8 are independently hydrogen or substituted or unsubstituted C 1 -C 3 alkyl.
7. The compound of claim 1 , wherein R 1 and R 7 are independently substituted or unsubstituted aryl or a substituted or unsubstituted fused ring system.
8. The compound of claim 7 , wherein R 1 is a substituted or unsubstituted fused ring system.
9. The compound of claim 8 , wherein R 1 is substituted or unsubstituted indole, substituted or unsubstituted naphthalene, or substituted or unsubstituted quinolone.
10. The compound of claim 7 , wherein R 7 is substituted or unsubstituted aryl or substituted or unsubstituted indole.
11. The compound of claim 10 , wherein R 7 is
and R 10 , R 11 , R 12 , R 13 and R 14 are independently hydrogen, F, Cl, Br, I, substituted or unsubstituted alkyl, substituted or unsubstituted alkoxy, substituted or unsubstituted amine, thiosulfinate, thiosulfonate, thioamide, sulfimide, sulfoximide, sulfonediimine, or sulfur halide.
12. The compound of claim 10 , wherein R 7 is
and R 10 , R 11 , R 12 , R 13 , and R 14 are independently hydrogen, F, Cl, Br, I, CF 3 , OCH 3 , NO 2 , OCH 2 (C 6 H 4 ), C 6 H 4 , SO 2 CH 3 , or OCF 3 .
13. The compound of claim 1 , wherein R 2 is substituted or unsubstituted C 1 -C 3 alkyl.
14. The compound of claim 1 , wherein R 3 , R 4 , and R 5 are independently hydrogen, F, Cl, Br, I, or substituted or unsubstituted alkyl.
15. The compound of claim 14 , wherein R 3 , R 4 , and R 5 are hydrogen.
16. The compound of claim 1 , wherein R 15 is unsubstituted C 1 -C 6 alkyl.
17. The compound of claim 1 , wherein the compound is selected from the group consisting of:
18. The compound of claim 1 , wherein the compound is selected from the group consisting of:
19. A method for the treatment of pain or inflammation which comprises administering to a subject in need thereof a therapeutically effective amount of a compound according to claim 1 .
20. A pharmaceutical composition containing a compound according to claim 1 and a pharmaceutically acceptable carrier.